NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women | HIV.gov

NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women | HIV.gov

NIH Study: Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women An investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks safely and effectively prevents HIV acquisition in men who have sex with men and transgender women who have sex with men. This finding, from a planned interim analysis of study data, marks the first time a large-scale clinical trial has shown a systemic, long-acting form of HIV prevention to be highly effective.  LEARN MORE

NIAID Observes HIV Vaccine Awareness Day 2020 On HIV Vaccine Awareness Day 2020, NIAID honors the researchers and clinical study participants who play essential roles in advancing HIV vaccine development. While work toward an HIV vaccine continues, scientists also are addressing a new pandemic—coronavirus disease 2019 (COVID-19). LEARN MORE